НовостиBenzingaLifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65 LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65 Benzinga 2026.11.09 13:17 (GMT+0) Открыть на Benzinga Другие новости